ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients
July 22, 2021ERYTECH today announced its intention to move forward towards the submission of a BLA to the US Food and Drug Administration for eryaspase in hypersensitive acute lymphoblastic leukemia patients following feedback from the agency in a pre-BLA meeting.
Pharma Sources Insight January 2025
